IRIDEX’s Cyclo G6 approved for glaucoma treatment in Europe — 4 highlights

IRIDEX received its CE Mark to commercialize across Europe its first laser system in its class designed solely for use in treating glaucoma and its symptoms, according to News-Medical.

Advertisement

Here are four highlights:

1. The Cyclo G6 laser system is dedicated specifically to treat patients diagnosed with a range of glaucoma disease states. The system features the company’s MicroPulse tissue-sparing technology and a family of single use probes that connect to an intuitive, user-friendly laser console.

2. Keith Barton, MD, consultant ophthalmologist of glaucoma service of Moorfields Eye Hospital in London, England, said some studies of the Cyclo G6 have shown a 30 percent to 40 percent reduction in intraocular pressure, and adds the ability to reduce IOP without incisions nor using implants in a quick procedure is a highlight.

3. The Cyclo G6 laser system will be sold with two disposable probes, the MicroPulse 3 probe for use with a broad range of glaucoma patients and the G-Probe for later stage patients. The company also plans to introduce a series of additional new probes in the coming year that allow for additional applications in glaucoma treatment.

4. IRIDEX is a global provider of innovative laser systems, delivery devices and consumables in ophthalmology.

More articles on healthcare:
Los Alamitos Surgery Center to provide prostate cancer treatment: 4 things to know
SCA added to S&P SmallCap 600, HCA to buy Texas hospital for $96M — 4 key notes on ASC companies
Hip, knee replacement rates vary by up to 232% among Colorado insurers: 5 findings

Advertisement

Next Up in ASC News

Advertisement

Comments are closed.